NCT03966456 is a clinical trial of Chemotherapy in Thoracic Cancer, sponsored by The Affiliated Hospital of Qingdao University.

Who is sponsoring NCT03966456?

NCT03966456 is sponsored by The Affiliated Hospital of Qingdao University.

What drugs are being tested in NCT03966456?

Interventions in NCT03966456: Chemotherapy.

What condition does NCT03966456 study?

NCT03966456 studies Thoracic Cancer, Gynecologic Cancer, Abdomen Tumors, Malignant Melanoma.

Is NCT03966456 still recruiting?

NCT03966456 is currently status unknown. Last updated 29 May 2019.

Last reviewed 2019-05-29 · How we verify

NCT03966456

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real World Study of Four PD-1 Agents in China

Status unknown Last updated 29 May 2019

What this trial tests

trial testing Chemotherapy in Thoracic Cancer in 500 participants. Status unknown.

Timeline

1 June 2018

Primary endpoint
1 June 2021

1 June 2023

Quick facts

Lead sponsor	The Affiliated Hospital of Qingdao University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 June 2018
Primary completion	1 June 2021
Estimated completion	1 June 2023
Sites	1 location across China

Drugs / interventions tested

Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Thoracic Cancer — all drugs for Thoracic Cancer →
Gynecologic Cancer — all drugs for Gynecologic Cancer →
Abdomen Tumors — all drugs for Abdomen Tumors →
Malignant Melanoma — all drugs for Malignant Melanoma →

Sponsor

The Affiliated Hospital of Qingdao University

Who can join

Adults 18 to 90, any sex, with Thoracic Cancer or Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Intra-Abdominal Malignant Melanoma: Challenging Aspects of Epidemiology, Clinical and Paraclinical Diagnosis and Optimal Treatment-A Literature Review.
Ionescu S, Nicolescu AC, Madge OL, Simion L, et al · · 2022 · cited 12× · PMID 36140455 · DOI 10.3390/diagnostics12092054
Efficacy and Biomarkers of Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Receiving Different PD-1 Agents in Northern China: A Real-world Clinical Study
Jiang M, Zhang X. · · 2020 · DOI 10.21203/rs.3.rs-130708/v1

Verify or expand the search:

Other trials of Chemotherapy

Trials testing the same drug.

NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting

Other recruiting trials for Thoracic Cancer

Currently open trials in the same condition.

NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting
NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT06669104 — Thoracic Surgery by the Medtronic Hugo™ Robotic System · recruiting
NCT06633224 — Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT · recruiting
NCT05375643 — SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention) · NA · recruiting

Other The Affiliated Hospital of Qingdao University trials

Trials by the same sponsor.

NCT07485920 — A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedani · Phase 4 · not yet recruiting
NCT07465861 — Bed Rest Duration and Outcomes in Endoscopic Skull Base Reconstruction · NA · not yet recruiting
NCT07453771 — Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma · NA · not yet recruiting
NCT07404709 — Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Ste · Phase 1, PHASE2 · not yet recruiting
NCT07167342 — The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03966456 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Qingdao University
Last refreshed: 29 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03966456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing